U.S. markets closed

Cyteir Therapeutics, Inc. (CYT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.0900+0.0300 (+0.98%)
At close: 04:00PM EST

Cyteir Therapeutics, Inc.

128 Spring Street
Building A Suite 510
Lexington, MA 02421
United States
857 285 4140

Full Time Employees46

Key Executives

NameTitlePayExercisedYear Born
Mr. Joseph S. ZakrzewskiIndependent Investor & Independent Chairman of the Board81.5kN/A1962
Dr. Markus F. Renschler M.D.President, CEO & Director718.62kN/A1961
Mr. Timothy RombergerIndependent Director43.22kN/A1972
Dr. Kevin Mills Ph.D.Co-FounderN/AN/AN/A
Mr. David G. GaieroCFO & TreasurerN/AN/A1978
Dr. Tom O'Shea Ph.D.Senior Vice President of Clinical Pharmacology & Preclinical DevelopmentN/AN/AN/A
Dr. Krisztina Nemenyi Ph.D.Senior Vice President of Regulatory Affairs and QualityN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the oncology therapeutics. Its lead product CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. Cyteir Therapeutics, Inc. was incorporated in 2012 and is headquartered in Lexington, Massachusetts.

Corporate Governance

Cyteir Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.